These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11583189)

  • 1. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
    Di Leo A; Larsimont D; Gancberg D; Jarvinen T; Beauduin M; Vindevoghel A; Michel J; Focan CH; Ries F; Gobert PH; Closon-Dejardin MT; Dolci S; Rouas G; Paesmans M; Lobelle JP; Isola J; Piccart MJ
    Ann Oncol; 2001 Aug; 12(8):1081-9. PubMed ID: 11583189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
    J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
    Piccart MJ; Di Leo A; Beauduin M; Vindevoghel A; Michel J; Focan C; Tagnon A; Ries F; Gobert P; Finet C; Closon-Dejardin MT; Dufrane JP; Kerger J; Liebens F; Beauvois S; Bartholomeus S; Dolci S; Lobelle JP; Paesmans M; Nogaret JM
    J Clin Oncol; 2001 Jun; 19(12):3103-10. PubMed ID: 11408507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
    Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
    O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI
    Breast Cancer Res Treat; 2011 Jul; 128(2):401-9. PubMed ID: 21519837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
    Hertel PB; Tu D; Ejlertsen B; Jensen MB; Balslev E; Jiang S; O'Malley FP; Pritchard KI; Shepherd LE; Bartels A; Brünner N; Nielsen TO
    Breast Cancer Res Treat; 2012 Feb; 132(1):225-34. PubMed ID: 22160637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites.
    Durbecq V; Di Leo A; Cardoso F; Rouas G; Leroy JY; Piccart M; Larsimont D
    Breast Cancer Res Treat; 2003 Feb; 77(3):199-204. PubMed ID: 12602919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.
    Paik S; Bryant J; Tan-Chiu E; Yothers G; Park C; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2000 Dec; 92(24):1991-8. PubMed ID: 11121461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
    de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
    Loi S; Sirtaine N; Piette F; Salgado R; Viale G; Van Eenoo F; Rouas G; Francis P; Crown JP; Hitre E; de Azambuja E; Quinaux E; Di Leo A; Michiels S; Piccart MJ; Sotiriou C
    J Clin Oncol; 2013 Mar; 31(7):860-7. PubMed ID: 23341518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.
    Eiermann W; Graf E; Ataseven B; Conrad B; Hilfrich J; Massinger-Biebl H; Vescia S; Loibl S; von Minckwitz G; Schumacher M; Kaufmann M;
    Eur J Cancer; 2010 Jan; 46(1):84-94. PubMed ID: 19879750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
    Colozza M; Sidoni A; Mosconi AM; Cavaliere A; Bisagni G; Gori S; De Angelis V; Frassoldati A; Cherubini R; Bian AR; Rodino C; Mazzocchi B; Mihailova Z; Bucciarelli E; Tonato M;
    Clin Breast Cancer; 2005 Aug; 6(3):253-9. PubMed ID: 16137437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
    N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
    Munro AF; Bartels A; Balslev E; Twelves CJ; Cameron DA; Brünner N; Bartlett JM
    Breast Cancer Res; 2013 Apr; 15(2):R31. PubMed ID: 23570501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.
    Bernard-Marty C; Mano M; Paesmans M; Accettura C; Munoz-Bermeo R; Richard T; Kleiber K; Cardoso F; Lobelle JP; Larsimont D; Piccart MJ; Di Leo A
    Ann Oncol; 2003 May; 14(5):693-8. PubMed ID: 12702521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
    Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
    N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.